SXP (Solar) 24-hour volatility at 43.3%: surged to a high of $0.0043 before quickly falling back to $0.003, driven by exchange delisting and abnormal buy orders.
Bitget Pulse2026/03/31 23:03Volatility Overview
In the past 24 hours, the price of SXP surged from a low of $0.003 to a high of $0.0043, with an amplitude of 43.3%. Currently, it is quoted at $0.003, showing a general pattern of pump followed by sell-off and pullback. The 24-hour trading volume is approximately $2.98 million, an increase of 5.5% compared to the previous day, indicating rising market activity.
Brief Analysis of the Abnormal Fluctuations
- The European exchange Bitvavo announced the delisting of SXP (effective March 30, 2026), combined with similar moves from Binance, causing panic selling and leading to a rapid price drop of about 10%-30%.
- X community monitoring shows an abnormal surge in buy orders (2.7x to 10.6x), which pushed a short-term pump, but was followed by selling pressure, resulting in a pullback.
Market Views and Outlook
Market sentiment remains cautious. Traders in the discussions on X warn of short-term risk of pullback, suggesting to wait for confirmation of a rebound at the $0.003 support level and avoid chasing highs; some opinions regard the abnormal trading volumes as a sign of “smart money” accumulation, but delisting events are shaping bearish expectations, and the short term may test the $0.0025-$0.003 support range.
Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, for information purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
AMD (AMD.US) Surpasses $1 Trillion Market Cap and Begins Competing for "Computing Power Definition Rights"! Officially Announces $8.2 Billion Acquisition of Fei-Fei Li's World Labs
AMD has agreed to acquire World Labs for $8.2 billion, thereby gaining access to the artificial intelligence startup founded by industry pioneer and researcher Fei-Fei Li. This acquisition is expected to help AMD plan its future hardware launches by bringing in a team of top researchers and their models, as well as deep insights into trends in the field of artificial intelligence.
A Major Reversal Amid the U.S. Bond Selloff! Bond Market Veteran Bianco Turns Bullish for the First Time in Six Years, Calling 5% Yield a "Value Buy Opportunity"
Currently, as benchmark U.S. Treasury yields surge to their highest levels in nearly two decades, bond market veteran Jim Bianco has loosened his bearish stance for the first time and is gradually building long positions as a "value buyer."
Crypto prices
More
